Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange alone or in
combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine
release syndrome. It is hypothesized that dual intervention of acute apheretic depletion of
cytokines and concomitant suppression of production will produce superior amelioration of the
cytokine load and to help to prevent cytokine load rebound. This protocol is envisioned as a
pilot study (n=20) for hypothesis generation for future investigation.